Full Breakdown
dsm-firmenich Divests Animal Nutrition & Health Business to CVC Capital Partners
2/10/2026, 7:03:07 PM
Overview of the Transaction
dsm-firmenich, a global leader in nutrition, health, and beauty, has announced its agreement to divest its Animal Nutrition & Health (ANH) business to CVC Capital Partners for an enterprise value of approximately €2.2 billion (about $2.6 billion). This transaction includes an earnout of up to €0.5 billion and allows dsm-firmenich to retain a 20% equity stake in the newly formed companies. The divestment is part of dsm-firmenich's strategic shift towards focusing solely on consumer goods, particularly in the nutrition and beauty sectors.
Financial Implications and Structure
The ANH business, which generated annualized net sales of around €3.5 billion in 2025 and employs approximately 8,000 people, will be split into two standalone entities: the Solutions Company and the Essential Products Company, both based in Kaiseraugst, Switzerland. The Solutions Company will focus on performance solutions, premixes, and precision services, while the Essential Products Company will handle vitamins, carotenoids, and aroma ingredients. The overall enterprise value of the ANH divestment, including a previous sale of its feed enzymes business to Novonesis for €1.5 billion, totals €3.7 billion.
dsm-firmenich expects to receive about €1.2 billion upon closing, which includes approximately €0.6 billion in net cash proceeds, alongside debt and liability transfers. The company will also provide the Essential Products Company with a loan facility of up to €450 million to support its operations.
Strategic Rationale
This divestment marks the final step in dsm-firmenich's strategic transformation into a consumer-focused entity. CEO Dimitri de Vreeze stated that the transaction reflects the company's commitment to accelerating growth and creating long-term value for stakeholders. The move is seen as a response to pressures in the animal nutrition market, particularly from cheaper ingredients sourced from China, and aims to enhance the company's focus on human nutrition and beauty products.
Market Reactions and Analyst Perspectives
Following the announcement, shares of dsm-firmenich fell by over 5%, indicating investor concerns regarding the deal's valuation and its implications for future growth. Analysts have noted that while the divestment simplifies the company's structure, the smaller-than-expected share buyback program of €500 million could dampen market sentiment. Barclays analysts emphasized that the transaction brings closure to a complex separation process but highlighted the need for improved performance in the core business to restore investor confidence.
Official Statements
Steven Buyse, Managing Partner at CVC, expressed enthusiasm about the partnership, stating, “This transaction represents a unique opportunity to create two new leading companies in the animal nutrition & health space.” He emphasized the potential for value creation through innovation and efficiency in animal farming.
What's Next
The transaction is expected to be completed by the end of 2026, pending regulatory approvals and the establishment of the new standalone companies. dsm-firmenich will report its full-year 2025 results on February 12, 2026, reflecting the reclassification of ANH as discontinued operations. The company aims to maintain a stable dividend policy of €2.50 per share, with progressive increases over time, as part of its commitment to long-term shareholder value.
